LTR Pharma Secures Indian Patent Supporting SPONTAN® and ROXUS®

09 November 2026

Highlights

- Indian Patent Office formally grants Patent No. 605429, titled Formulations and Methods for Treating Erectile Dysfunction.
- Granted claims protect defined formulation characteristics relating to the Company's intranasal formulation technology.
- Patent protection extends to May 2041, subject to applicable maintenance requirements and continued validity.
- Grant represents a further milestone in LTR Pharma's international intellectual property strategy supporting SPONTAN® and ROXUS®.

LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company") is pleased to announce that the Indian Patent Office has formally granted Patent No. 605429, titled *Formulations and Methods for Treating Erectile Dysfunction*. The patent protects defined formulation characteristics of the intranasal technology supporting the Company's SPONTAN® and ROXUS® products.

The grant represents a further milestone in the Company's international intellectual property strategy, supporting its ongoing clinical development and commercialisation programs.

LTR Pharma Executive Chairman, Lee Rodne, said:

"The grant of this patent in India is a positive milestone for LTR Pharma, further strengthening the intellectual property portfolio supporting SPONTAN and ROXUS.

We are pleased with the scope of the granted claims and the additional protection they provide for our intranasal formulation technology.

Protecting our intellectual property remains an important part of our strategy as we advance our clinical and commercial programs."

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary rapid-acting intranasal platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our Investor Centre or scan the QR code.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com